CollPlant Biotechnologies (CLGN) Expected to Announce Quarterly Earnings on Wednesday

CollPlant Biotechnologies (NASDAQ:CLGN) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, June 4th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $9.76 million for the quarter.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its earnings results on Wednesday, March 26th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.08. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.36 million. CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. On average, analysts expect CollPlant Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CollPlant Biotechnologies Stock Performance

CollPlant Biotechnologies stock opened at $1.93 on Wednesday. The firm has a market capitalization of $22.11 million, a P/E ratio of -1.25 and a beta of 1.24. CollPlant Biotechnologies has a 1 year low of $1.55 and a 1 year high of $6.00. The business has a 50-day moving average of $2.25 and a 200-day moving average of $3.24.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of CollPlant Biotechnologies in a research report on Thursday, March 27th.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.